Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.
1:17-cv-00227
Overview
Parties
Defendant
Novo Nordisk Inc. Operating Company
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Teva Pharmaceuticals USA, Inc. Operating Company
Represented By
5 Attorneys ListedShaw Keller LLP
1105 North Market Street, 12th Floor, Wilmington, DE 19801
Plaintiff
Novo Nordisk A/S NPE (Individual / Inventor)
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 16 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Fresenius Kabi USA, LLC v. Novo Nordisk A/S
Pfizer Inc. v. Novo Nordisk A/S
Patents Involved
There are 5 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6268343
Derivatives of GLP-1 analogs
|
Filed: 1999-02-26
Issued: 2001-07-31
|
Expired (Term Ended)
+1273d PTA
Expires: 2022-08-22
|
|
|
US9265893
Injection button
|
Filed: 2008-01-21
Issued: 2016-02-23
|
Active (5.8 yrs remaining)
+1707d PTA
Expires: 2032-09-23
|
|
|
USRE41956
Dose setting limiter
|
Filed: 2005-05-04
Issued: 2010-11-23
|
Expired (Term Ended)
Expires: 2021-01-21
|
|
|
US8114833
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
Filed: 2006-05-17
Issued: 2012-02-14
|
Expired (Term Ended)
+118d PTA
Expires: 2026-09-12
|
|
|
US8846618
Stable formulation of modified GLP-1
|
Filed: 2010-05-24
Issued: 2014-09-30
|
Active (3.5 yrs remaining)
Expires: 2030-05-24
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.
High PTA (+1273 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
29
Dispositive
0
Granted
0
Denied
0
Pending / Review
18
Motions by Category
Key Dispositive Motions & Rulings